Mostrando 5 resultados de: 5
Filtros aplicados
Subtipo de publicación
Article(5)
Publisher
Canadian Journal of Cardiology(2)
European Heart Journal(1)
Gastroenterology(1)
New England Journal of Medicine(1)
Ezetimibe added to statin therapy after acute coronary syndromes
ArticleAbstract: BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk ofPalabras claves:Autores:Armstrong P., Aylward P.E., Azize G., Ballantyne C., Bassand J., Beloscar J., Beltrano M., Berra F., Blazing M.A., Bluguermann J., Blumberg E., Bohula E.A., Bono J., Brady A.J.B., Braunwald E., Britto F., Califf R.M., Cannon C.P., Carlessi C., Carlevaro O., Carrageta M., CARTASEGNA L.U.I.S., Caruso O., Casalins M., Castoldi M., Centeno E., Cocco N., Colombo H., Corbalan R., Dalby A.J., Darius H., De Ferrari G.M., de Lemos J., De Lucca P., Dellatorre M., Dellborg M., Duris T., Duronto E., Egido J., Fanuele M., Farnier M., Fernandez H., Fernández R.O., Genest J., Giugliano R.P., Grande P., Guerrero R., Guneri S., Gurfinkel E., HOMINAL M.A., Im K.A., Isaza D., Jukema J.W., Keltai M., Kesaniemi A., Kleiman N.S., Lewis B.S., López-Sendón J.L., Lozada A.F., Mach F., MACIN S.M., Maffeo H., Mathur A., Maurer G., Mauro D., McCagg A., McGuire D., Milesi R., Mittal S., Musliner T.A., NANI S., Nicolau J.C., Ophuis T.O., Parkhomenko A.N., Pedersen T., Procopio G., Ramos H., Reddy K., Reges P., Reist C., Ricart J., Ruiz N., Ruzyllo W., Schmuck R., Seung K., Spinar J., Terns P., Tershakovec A.M., Theroux P., Tonkin A.M., Turri D., Van de Werf F., Viso M., Voitk J., White H.D., White J.A., Wiviott S.D., Yan Duarte, Zarandon R.Fuentes:scopusNovel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
ArticleAbstract: Background: Cholesterol and blood pressure (BP) can be effectively and safely lowered with statin drPalabras claves:Autores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Dans A.M., DIaz R., Fodor G.J., Held C., Jansky P., Keltai K., Keltai M., Kim J.H., Kunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Pogue J., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusLowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
ArticleAbstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) ePalabras claves:Cardiovascular disease, Primary Prevention, statinsAutores:Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusSafety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin
ArticleAbstract: Background & Aims: Proton pump inhibitors (PPIs) are effective at treating acid-related disorders. TPalabras claves:bacteria, CVD, Reflux, ThrombosisAutores:Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Dyal L., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Hart R.G., Hori M., Kakkar A.K., Keltai M., Kim J.H., Lanas F.T., Leong D.P., Lewis B.S., Liang Y., Lonn E.M., Maggioni A.P., Metsarinne K.P., Moayyedi P., Muehlhofer E., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Shestakovska O., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Verhamme P.B., Vinereanu D., Widimsky P., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusRationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial
ArticleAbstract: Background Long-term aspirin prevents vascular events but is only modestly effective. Rivaroxaban alPalabras claves:Autores:Aboyans V., Alings M., Anand S.S., Avezum A.J., Bhatt D.L., Bosch J.J., Branch K.R.H., Bruns N.C., Chen E., Commerford P.J., Connolly S.J., Dagenais G.R., Dans A.M., DIaz R., Eikelboom J.W., Ertl G., Felix Camilo, Fox K.A.A., Guzik T.J., Ha J.W., Hart R.G., Hori M., Kakkar A.K., Keltai K., Keltai M., Kim J.H., Lamy A., Lanas F., Lanius V., Leong D.P., Lewis B.S., Liang Y., Liu L., Lonn E.M., Maggioni A.P., Metsarinne K.P., Misselwitz F., Moayyedi P., O’Donnell M., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Piegas L.S., Pogosova N., Probstfield J.L., Rydén L.E., Sharma M., Steg P.G., Störk S., Tonkin A.M., Torp-Pedersen C., Varigos J.D., Verhamme P.B., Vinereanu D., Widimsky P., Yuan F., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopus